Ipsen, Salk Institute renew research agreement
Under the renewal agreement, Ipsen will provide funding for research programs carried out at the Salk Institute by researchers on therapeutic concepts for the treatment of pituitary adenomas,
HAYA Therapeutics has secured fast track designation from the US Food and Drug Administration (FDA) for its investigational therapy, HTX-001, to treat symptomatic non-obstructive hypertrophic cardiomyopathy (nHCM).